TRS01
Phase 3Small molecule
TRS01 is one of 6 small molecule programs targeting Non-Infectious Anterior Uveitis. It is currently in Phase 3.
1
Indications
3
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Non-Infectious Anterior Uveitis
#DrugCompanyPhaseTrials
1Pred Forte
NovartisPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Dexamethasone Phosphate
EEyegate Pharmaceuticals, Inc.
Phase 3
Prograf
VVeloxis Pharmaceuticals
Phase 2
LX211
LLux Biosciences, Inc.
Phase 3
TRS01
TTarsier Pharma
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Non-Infectious Anterior Uveitis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TRS01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTarsier Pharma